Arecor Therapeutics plc (FRA:6UI)

Market Cap	31.35M +25.6%
Revenue (ttm)	5.90M +3.3%
Net Income	-9.45M
EPS	-0.26
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	n/a
Open	0.6200
Previous Close	0.7200
Day's Range	0.6200 - 0.7200
52-Week Range	0.4840 - 0.9350
Beta	n/a
RSI	24.89
Earnings Date	Apr 20, 2026

About Arecor Therapeutics

Arecor Therapeutics plc, a clinical stage biotechnology company, develops innovative medicines that address significant unmet patient needs in the United Kingdom. The company through its proprietary reformulation technology platform, Arestat, developing a portfolio of proprietary products in diabetes and other indications, as well as working with pharmaceutical and biotechnology companies to deliver enhanced reformulations of therapeutic products. It also offers Ogluo which is used to treat severe hypoglycaemia events in patients with diabetes;...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2007
• Employees: 44
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 6UI

Financial Performance

In 2024, Arecor Therapeutics's revenue was 5.05 million, an increase of 10.50% compared to the previous year's 4.57 million. Losses were -10.24 million, 19.7% more than in 2023.

Financial numbers in GBP